microRNAs: Promising biomarkers and therapeutic targets of acute myocardial ischemia

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 305-315

  Fasanaro, Pasquale ^a   D’Alessandra, Yuri ^b   Magenta, Alessandra ^a   Pompilio, Giulio ^b   Capogrossi, Maurizio C ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Acute myocardial ischemia; Ischemic diseases; MicroRNAs; MiRNA based therapy

Indexed keywords

LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 1; MICRORNA 122; MICRORNA 133A; MICRORNA 133B; MICRORNA 145; MICRORNA 15; MICRORNA 150; MICRORNA 16; MICRORNA 184; MICRORNA 195; MICRORNA 200; MICRORNA 206; MICRORNA 208A; MICRORNA 21; MICRORNA 210; MICRORNA 222; MICRORNA 223; MICRORNA 24; MICRORNA 29; MICRORNA 31; MICRORNA 320; MICRORNA 34A; MICRORNA 375; MICRORNA 423 5P; MICRORNA 499; MICRORNA 92A; RNA INDUCED SILENCING COMPLEX; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ANGIOGENESIS; APOPTOSIS; ARTICLE; DOWN REGULATION; DRUG TARGETING; ECHOCARDIOGRAPHY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; METABOLIC INHIBITION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE REACTION; UPREGULATION; ACUTE CORONARY SYNDROME; ANIMAL; DRUG EFFECTS; METABOLISM; MYOCARDIAL ISCHEMIA;

ACUTE CORONARY SYNDROME; ANIMALS; BIOMARKERS; HUMANS; MICRORNAS; MYOCARDIAL ISCHEMIA;

EID: 84937142954     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990011     Document Type: Article

References (122)

1. [1] Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007; 8: 215-39.
2. [2] Watanabe Y, Kanai A. Systems Biology Reveals MicroRNAMediated Gene Regulation. Front Genet 2011; 2: 29.
3. [3] Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F. microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther 2010; 125(1): 92-104.
4. [4] Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010; 121(8): 1022-32.
5. [5] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
6. [6] Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12(2): 99-110.
7. [7] van Rooij E. The art of microRNA research. Circ Res 2011; 108(2): 219-34.
8. [8] Vasudevan S. Posttranscriptional Upregulation by MicroRNAs. Wiley Interdiscip Rev RNA 2012; 3(3): 311-30.
9. [9] Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11(9): 597-610.
10. [10] Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11(3): 228-34.
11. [11] Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466(7308): 835-40.
12. [12] Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
13. [13] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
14. [14] Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res 2011; 39(16): 6845-53.
15. [15] Elefant N, Altuvia Y, Margalit H. A wide repertoire of miRNA binding sites: prediction and functional implications. Bioinformatics 2011; 27(22): 3093-101.
16. [16] Forman JJ, Coller HA. The code within the code: microRNAs target coding regions. Cell Cycle 2010; 9(8): 1533-41.
17. [17] Lal A, Navarro F, Maher CA, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3’UTR microRNA recognition elements. Mol Cell 2009; 35(5): 610-25.
18. [18] Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP. Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell 2010; 38(6): 789-802.
19. [19] Chi SW, Hannon GJ, Darnell RB. An alternative mode of microRNA target recognition. Nat Struct Mol Biol 2012; 19(3): 321-7.
20. [20] Fasanaro P, Romani S, Voellenkle C, Maimone B, Capogrossi MC, Martelli F. ROD1 is a seedless target gene of hypoxia-induced mir-210. PLoS One 2012; 7(9): e44651.
21. [21] Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res 2011; 717(1-2): 85-90.
22. [22] Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the MicroRNA spectrum between serum and plasma. PLoS One 2012; 7(7): e41561.
23. [23] Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18(10): 997-1006.
24. [24] Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vascul Pharmacol 2011; 55(4): 111-8.
25. [25] Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 2011; 31(11): 2383-90.
26. [26] D’Alessandra Y, Pompilio G, Capogrossi MC. MicroRNAs and myocardial infarction. Curr Opin Cardiol 2012; 27(3): 228-35.
27. [27] Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32(2): 326-48.
28. [28] Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108(12): 5003-8.
29. [29] Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13(4): 423-33.
30. [30] Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2011; 78(9): 838-48.
31. [31] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9(6): 654-9.
32. [32] Condorelli G, Latronico MV, Dorn GW, II. microRNAs in heart disease: putative novel therapeutic targets? Eur Heart J 2010; 31(6): 649-58.
33. [33] van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008; 103(9): 919-28.
34. [34] Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3(9): e3148.
35. [35] Jung M, Schaefer A, Steiner I, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010; 56(6): 998-1006.
36. [36] Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012; 93(4): 555-62.
37. [37] D’Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31(22): 2765-73.
38. [38] Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012; 14(2): 147-54.
39. [39] Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. Rna 2006; 12(7): 1197-205.
40. [40] Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438(7068): 685-9.
41. [41] Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3(2): 87-98.
42. [42] Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19(6): 1116-22.
43. [43] Ivan M, Harris AL, Martelli F, Kulshreshtha R. Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med 2008; 12(5A): 1426-31.
44. [44] Devlin C, Greco S, Martelli F, Ivan M. miR-210: More than a silent player in hypoxia. IUBMB Life 2011; 63(2): 94-100.
45. [45] Gorospe M, Tominaga K, Wu X, Fahling M, Ivan M. Post-Transcriptional Control of the Hypoxic Response by RNA-Binding Proteins and MicroRNAs. Front Mol Neurosci 2011; 4: 7.
46. [46] Suarez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res 2009; 104(4): 442-54.
47. [47] Wang S, Olson EN. AngiomiRs--key regulators of angiogenesis. Curr Opin Genet Dev 2009; 19(3): 205-11.
48. [48] Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 2005; 14(4): 170-5.
49. [49] Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers 2009; 27(6): 255-68.
50. [50] van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105(35): 13027-32.
51. [51] Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82(1): 21-9.
52. [52] Ren XP, Wu J, Wang X, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heatshock protein 20. Circulation 2009; 119(17): 2357-66.
53. [53] Port JD, Walker LA, Polk J, Nunley K, Buttrick PM, Sucharov CC. Temporal expression of miRNAs and mRNAs in a mouse model of myocardial infarction. Physiol Genomics 2011; 43(19): 1087-95.
54. [54] Cheng Y, Zhu P, Yang J, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via antiapoptosis through its target PDCD4. Cardiovasc Res 2010; 87(3): 431-9.
55. [55] Wang X, Zhang X, Ren XP, et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/ reperfusion-induced cardiac injury. Circulation 2010; 122(13): 1308-18.
56. [56] Dong S, Cheng Y, Yang J, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009; 284(43): 29514-25.
57. [57] Shi B, Guo Y, Wang J, Gao W. Altered expression of microRNAs in the myocardium of rats with acute myocardial infarction. BMC Cardiovasc Disord 2010; 10: 11.
58. [58] He B, Xiao J, Ren AJ, et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci 2011; 18: 22.
59. [59] Hullinger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012; 110(1): 71-81.
60. [60] Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31(6): 659-66.
61. [61] Olivieri F, Spazzafumo L, Santini G, et al. Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging. Mech Ageing Dev 2012; 133(11-12): 675-85.
62. [62] Ye Y, Perez-Polo JR, Qian J, Birnbaum Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics 2011; 43(10): 534-42.
63. [63] Frost RJ, van Rooij E. miRNAs as therapeutic targets in ischemic heart disease. J Cardiovasc Transl Res 2010; 3(3): 280-9.
64. [64] Dorn GW, 2nd. MicroRNAs in cardiac disease. Transl Res 2011; 157(4): 226-35.
65. [65] Heyn J, Hinske C, Mohnle P, Luchting B, Beiras-Fernandez A, Kreth S. MicroRNAs as potential therapeutic agents in the treatment of myocardial infarction. Curr Vasc Pharmacol 2011; 9(6): 733-40.
66. [66] Tang Y, Zheng J, Sun Y, Wu Z, Liu Z, Huang G. MicroRNA-1 Regulates Cardiomyocyte Apoptosis by Targeting Bcl-2. Int Heart J 2009; 50(3): 377-87.
67. [67] Shan ZX, Lin QX, Fu YH, et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 2009; 381(4): 597-601.
68. [68] Lu Y, Zhang Y, Shan H, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischemic cardioprotection. Cardiovasc Res 2009; 84(3): 434-41
69. [69] Bostjancic E, Zidar N, Stajner D, Glavac D. MicroRNA miR-1 is upregulated in remote myocardium in patients with myocardial infarction. Folia Biol (Praha) 2010; 56(1): 27-31.
70. [70] Rau F, Freyermuth F, Fugier C, et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol 2011; 18(7): 840-5.
71. [71] Goldoni D, Yarham JM, McGahon MK, et al. A novel dualfluorescence strategy for functionally validating microRNA targets in 3’ untranslated regions: regulation of the inward rectifier potassium channel Kir2.1 by miR-212. Biochem J 2012; 448(1): 103-13.
72. [72] Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129(2): 303-17.
73. [73] Yin C, Salloum FN, Kukreja RC. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res 2009; 104(5): 572-5.
74. [74] Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456(7224): 980-4.
75. [75] Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011; 208(3): 549-60.
76. [76] Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011; 124(6): 720-30.
77. [77] Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16(1): 23-9.
78. [78] Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 2010; 87(3): 535-44.
79. [79] Bonauer A, Carmona G, Iwasaki, M et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324(5935): 1710-3.
80. [80] Francis SE, Goh KL, Hodivala-Dilke K, et al. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 2002; 22(6): 927-33.
81. [81] De Celle T, Vanrobaeys F, Lijnen P, et al. Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia-reperfusion. Exp Physiol 2005; 90(4): 593-606.
82. [82] Kloosterman WP, Steiner FA, Berezikov E, et al. Cloning and expression of new microRNAs from zebrafish. Nucleic Acids Res 2006; 34(9): 2558-69.
83. [83] Wang JX, Jiao JQ, Li Q, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2011; 17(1): 71-8.
84. [84] van Rooij E, Quiat D, Johnson BA, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009; 17(5): 662-73.
85. [85] Baldwin KM, Haddad F. Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle. J Appl Physiol 2001; 90(1): 345-57.
86. [86] Hosoda T, Zheng H, Cabral-da-Silva M, et al. Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 2011; 123(12): 1287-96.
87. [87] van Solingen C, Seghers L, Bijkerk R, et al. Antagomir-Mediated Silencing of Endothelial Cell Specific MicroRNA-126 Impairs Ischemia-Induced Angiogenesis. J Cell Mol Med 2009; 13(8A): 1577-85.
88. [88] Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010; 115(3): 163-9.
89. [89] Xu C, Lu Y, Pan Z, et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007; 120(Pt 17): 3045-52.
90. [90] Limana F, Esposito G, D’Arcangelo D, et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS One 2011; 6(6): e19845.
91. [91] Limana F, Germani A, Zacheo A, et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 2005; 97(8): e73-e83.
92. [92] De Mori R, Straino S, Di Carlo A, et al. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol 2007; 27(11): 2377-83.
93. [93] Greco S, De Simone M, Colussi C, et al. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J 2009; 23(10): 3335-46.
94. [94] Straino S, Germani A, Di Carlo A, et al. Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation 2004; 110(21): 3341-8.
95. [95] Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11(9): 670-7.
96. [96] Magenta A, Cencioni C, Fasanaro P, et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 2011; 18(10): 1628-39.
97. [97] Zaccagnini G, Martelli F, Fasanaro P, et al. p66ShcA modulates tissue response to hindlimb ischemia. Circulation 2004; 109(23): 2917-23.
98. [98] Zaccagnini G, Martelli F, Magenta A, et al. p66(ShcA) and oxidative stress modulate myogenic differentiation and skeletal muscle regeneration after hind limb ischemia. J Biol Chem 2007; 282(43): 31453-9.
99. [99] Dharap A, Bowen K, Place R, Li LC, Vemuganti R. Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome. J Cereb Blood Flow Metab 2009; 29(4): 675-87.
100. [100] Lou YL, Guo F, Liu F, et al. miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem 2012; 370(1-2): 45-51.
101. [101] Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemiareperfusion injury. Am J Surg 2001; 181(2): 160-6.
102. [102] Yu CH, Xu CF, Li YM. Association of MicroRNA-223 expression with hepatic ischemia/reperfusion injury in mice. Dig Dis Sci 2009; 54(11): 2362-6.
103. [103] Shen J, Yang X, Xie B, et al. MicroRNAs regulate ocular neovascularization. Mol Ther 2008; 16(7): 1208-16.
104. [104] Adachi T, Nakanishi M, Otsuka Y et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem 2010; 56(7): 1183-5.
105. [105] Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391(1): 73-7.
106. [106] Cheng Y, Tan N, Yang J, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010; 119(2): 87-95.
107. [107] Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 3(6): 499-506.
108. [108] Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009; 55(11): 1944-9.
109. [109] Meder B, Keller A, Vogel B, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2010; 106(1): 13-23.
110. [110] Cheng Y, Wang X, Yang J, et al. A translational study of urine miRNAs in acute myocardial infarction. J Mol Cell Cardiol 2012; 53(5): 668-76.
111. [111] Zhang R, Niu H, Ban T, et al. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int J Cardiol 2013; 166(1): 259-60.
112. [112] Matsumoto S, Sakata Y, Nakatani D, et al. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochem Biophys Res Commun 2012; 427(2): 280-4
113. [113] Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60(4): 290-9.
114. [114] Hu S, Huang M, Li Z, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010; 122(Suppl 11): S124-31.
115. [115] Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 2009; 284(50): 35134-43.
116. [116] Voellenkle C, van Rooij J, Guffanti A, et al. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. RNA 2012; 18(3): 472-84.
117. [117] Fasanaro P, D’Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008; 283(23): 15878-83.
118. [118] Huang M, Chen Z, Hu S, et al. Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation 2009; 120(Suppl 11): S230-7.
119. [119] Zhang Y, Zhang L, Chu W, et al. Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes. Cell Physiol Biochem 2010; 26(6): 991-8.
120. [120] Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011; 118(4): 217-26.
121. [121] Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011; 4(4): 446-54.
122. [122] De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. Circulation 2011; 124(18): 1936-44.